Give your patients access to latest AF treatment options Find a specialist hospital
Skip to main content
Cardiologist in lab coat reviews printed research at desk, emphasizing evidence supporting catheter ablation treatment.

ATRIAL FIBRILLATION

Persistent AF

Key trials exploring the role of FARAPULSE PFA

ADVANTAGE25,26

Prospective Multi-Centre Single-Arm Trial on Drug-Refractory, Symptomatic Persistent AF Patients

Discover the number of patients treated in key clinical trials.
515  patients
Key findings

AVANT GUARD40

Randomised Controlled IDE Trial of First-Line FARAPULSE PFA vs. Antiarrhythmic Drug Therapy in Persistent AF Patients

Discover the number of patients treated in key clinical trials.
310  patients
Key findings

ADVANTAGE21,22

Prospective Multi-Centre Single-Arm Trial on Drug-Refractory, Symptomatic Persistent AF Patients (2 Phases):

View phase 1 data sheet
View phase 2 data sheet
Discover the number of patients treated in key clinical trials.

Patients #

515 across two phases:

  • 260 Phase I
  • 255 phase II
Three people connected under a globe symbolising the patient population.

Patient Population

Persistent AF (PVI + PWA)

Location pin icon representing map marker for place identification.

Location

International (49 sites)

Checklist clipboard with pen icon, representing study goals and design for Boston Scientific’s clinical research and PFA leadership.

Study Goal & Design

Goal:

  • Phase I: IDE study to establish the safety and effectiveness of PVI+PWA using FARAWAVE
  • Phase II: IDE study to establish:
    • Safety and effectiveness of PVI+PWA using FARAWAVE catheter
    • Safety and effectiveness of CTI ablation using FARAPOINT focal-linear PFA catheter

Design:

  • Multicentre
  • Prospective
  • Single-arm
  • Open-label
  • Monitoring with ICM (Phase 2)
Boston Scientific drives PFA leadership with key findings and clinical trials for FARAPULSE™ in atrial fibrillation.

Key findings

  • Primary safety and efficacy endpoints were met
  • No reports of:
    • Stroke
    • PV stenosis
    • Oesophageal fistula
    • Pericardial tamponade
    • Major vascular access complication
  • Primary safety event rate 2.4%
  • Primary effectiveness event-free rate at 12 months comparable to paroxysmal AF reported outcomes (73.4%)*
  • 96.4% of patients treated with CTI line ablation with FARAPOINT had no recurrence of AFL

AVANT GUARD40

Randomised Controlled IDE Trial of First-Line FARAPULSE PFA vs. Antiarrhythmic Drug Therapy in Persistent AF Patients

View data sheet
Discover the number of patients treated in key clinical trials.

Patients #

310 first-line Persistent AF patients:

  • 207 FARAPULSE PFA
  • 103 AAD therapy
Three people connected under a globe symbolising the patient population.

Patient Population

PersAF (PVI+PWA)

Location pin icon representing map marker for place identification.

Location

International (58 global centres)

Checklist clipboard with pen icon, representing study goals and design for Boston Scientific’s clinical research and PFA leadership.

Study Goal & Design

Goal:

  • Compare FARAPULSE Pulsed Field Ablation (FARAWAVE Catheter) with antiarrhythmic drug (AAD) therapy as first-line treatment for patients with persistent AF, evaluating both safety and effectiveness.

Design:

  • Randomised controlled trial
  • Prospective
  • Multicentre
  • Continuous rhythm monitoring with LUX-Dx™ Insertable Cardiac Monitor (ICM)
  • 12-month follow-up
Boston Scientific drives PFA leadership with key findings and clinical trials for FARAPULSE™ in atrial fibrillation.

Key findings

  •  Primary safety and effectiveness endpoints met
  • Superior primary effectiveness versus AAD therapy (56.0% vs 30.1% at 12 months)
  • FARAPULSE reported higher freedom from recurrence at 12 months (51.7% vs 32.2%)
  • Primary safety endpoint met: 5.1% major device- or procedure-related AE rate at 12 months, below the 12% safety performance goal

AF: Atrial fibrillation; AFL: Atrial flutter; CTI: Cavotricuspid isthmus; ICM: Implantable cardiac monitor; PAF: Persistent atrial fibrillation; PFA: Pulsed field ablation; PV: Pulmonary vein; PVI: Pulmonary vein isolation; PWA: Posterior wall ablation.
*Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.